← The record

Amino Acid Formula With Vitamins And Minerals (Three Formulations: Without Phenylalanine; Without Phenylalanine And Tyrosine; Without Valine, Leucine And Isoleucine)

Not recommended MetabolicAuthority RequiredNot applicable line

Nutritional management of phenylketonuria (PKU), tyrosinaemia, and maple syrup urine disease (MSUD) in children. These are formulation upgrades (pack size increase from 29 g to 36 g sachets, flavour change, and enhanced nutritional composition) of existing products.

1
Submissions
1 resub
2015–15
On the record
ICER range
Cost-min
Cost basis

Decision on record

1 decision
  • Meeting Nov 2011 Not recommended Medicinal food no PSD

Access path

1 submission · public record
  1. Mar 2015
    Recommended

    vs Existing formulations in 29 g sachets

  2. PBS listing · Authority Required
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
5.1 The PBAC noted advice from the Nutritional Products Working Party and had no significant concerns over the formulation upgrade for TYR Anamix Junior, MSUD Anamix Junior, PKU Anamix Junior products in terms of the appropriateness of the nutritional content of the products for their intended uses.PSD · Mar 2015
5.2 The PBAC accepted NPWP advice that it may be helpful for the PBS listings of these products to note the changes in formulation (vitamin D and amino acid composition) through an administrative note for a suggested period of 6 to 12 months.PSD · Mar 2015

Cost-effectiveness

Cost-minimisation analysis: new formulations priced on equivalent gram of protein basis to existing formulations.

Whilst the PBAC recommended the listing of the new formulations in 36 g sachet sizes on a cost-minimisation basis with the existing formulations in 29 g sachets at an equivalent cost per gram of protein, the PBAC suggested the Department monitor use and financial expenditure on these products. PBAC · 2015
Cost-effectiveness accepted

Decision context

PopulationChildren requiring nutritional management of phenylketonuria, tyrosinaemia, or maple syrup urine disease.

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Mar 2015 Recommended Existing formulations in 29 g sachets Cost-minimisation · Cost-minimisation

Similar precedents

By decision profile